Observations on the disappearance of the stealth property of pegylated liposomes: Effects of lipid dose and dosing frequency

Liposome Technology: Interactions of Liposomes with the Biological Milieu

Volumn , Issue , 2006, Pages 79-94

  Carstens, Myrra G ^a   Romberg, Birgit ^a   Oussoren, Christien ^a   Storm, Gert ^a   Laverman, Peter ^b   Boerman, Otto C ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847020264     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (30)

1. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303:1818.
2. Woodle MC, Storm G. Long Circulating Liposomes: Old Drugs, New Therapeutics. Berlin: Springer-Verlag, 1998.
3. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113:171.
4. Storm G, Crommelin DJA. Liposomes: quo vadis? Pharmaceut Sci Technol Today 1998; 1:19.
5. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes:effect of dose. Biochim Biophys Acta 1991; 1068:133.
6. Utkhede DR, Tilcock CP. Effect of lipid dose on the bio distribution and blood pool clearance kinetics of PEG-modified technetium-labeled lipid vesicles. J Liposome Res 1998; 8:381.
7. Awasthi V, Goins B, Klipper, R, Loredo R, Korvick D, PhillipsW. Imaging experimental osteomyelitis using radiolabeled liposomes. J Nucl Med 1998; 39:1089.
8. Goins B, Phillips W, Klipper R. Blood-pool imaging using technetium-99mlabeled liposomes. J Nucl Med 1996; 37:1374.
9. Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev 1999; 37:225.
10. Boerman OC, Laverman P, Oyen WJ, Corstens FH, Storm G. Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res 2000; 39:461.
11. Laverman P, Brouwers AH, Dams ET, et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther 2000; 293:996.
12. Oja CD, Semple SC, Chonn A, Cullis PR. Influence of dose on liposome clearance:Critical role of blood proteins. Biochim Biophys Acta 1996; 1281:31.
13. Laverman P, Carstens MG, Boerman OC, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 2001; 298:607.
14. Laverman P, Boerman OC, Oyen WJG, Corstens FHM, Storm G. In vivo applications of PEG liposomes: unexpected observations. Crit Rev Ther Drug Carrier Syst 2001; 18:551.
15. Goins B, Phillips WT, Klipper R. Repeat injection studies of technetium-99mlabeled PEG-liposomes in the same animal. J Liposome Res 1998; 265.
16. Oussoren C, Storm G. Effect of repeated i.v. administration on the circulation kinetics of poly(ethyleneglycol)-liposomes in rats. J Liposome Res 1999; 349.
17. Dams ET, Laverman P, Oyen WJ, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 2000; 292:1071.
18. Ishida T, Masuda K, Ichikawa T, I chihara M, Irimura K, Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm 2003; 255:167.
19. Ishida T, Maeda R, I chihara M, Irimura K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Cont Release 2003; 88:35.
20. Ishida T, Ichikawa T, I chihara M, Sadzuka Y, Kiwada H. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J Cont Release 2004; 95:403.
21. Wang XY, Ishida TI, chihara M, Kiwada H. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats J Cont Release 2005; 104:91.
22. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther 2005; 312:1020.
23. Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF. Repeated injections of PEG-PE liposomes generate antiPEG antibodies. Cell Mol Biol Lett 2005; 10:37.
24. Ishida, T, I chihara M, Harada M, Kashima S, Wang X, Kiwada H. IgM secreted in response to the first injection of PEGylated liposomes involves in induction of the ABC phenomenon. 31 Annual Meeting and Exposition of the Controlled Release Society, Honolulu, Hawaii, June 13, 2004.
25. Bradley AJ, Devine, DV. The complement system in liposome clearance: Can complement deposition be inhibited? Adv Drug Deliv Rev 1998; 32:19.
26. Moghimi SM, Gray TA. A single dose of intravenously injected poloxaminecoated long-circulating particles triggers macrophage clearance of subsequent doses in rats. Clin Sci 1997; 93:371.
27. Laverman P, Carstens MG, Storm G, Moghimi SM. Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. Biochim Biophys Acta 2001; 1526:227.
28. Daemen T, Regts J, Meesters M, Ten Kate MT, Bakker-Woudenberg IAJM, Scherphof GL. Toxicity of doxorubicin entrapped within long-circulating liposomes. J Control Release 1997; 44:1.
29. Storm G, ten Kate MT, Working PK, Bakker-Woudenberg IA. Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin Cancer Res 1998; 4:111.
30. Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J Immunol Methods 1997; 210:137.